Anul IX nr. 1

APÃRAREA NBC 15/2008CBRN medicalProdusul farmaceutic nu prezintã toxicitate ºiefecte secundare în dozele administrate. Animaleletratate au prezentat creºteri în greutate cu stimulareaapetitului. Administrat sub formã de unguent, în cazularsurii provocate de iradiere sau agenþi chimici, produsulfarmaceutic prezintã o penetrabilitate optimã în aplicareacutanatã, favorizând efecte biologice restauratoare, faptce probeazã calitãþile sale terapeutice. Produsul respectivnu determinã efecte alergice cutanate, fiind bine tolerat ºiabsorbit rapid în procesul de vindecare a plãgilor.Ca efecte biologice, administrarea sub formã decapsule a medicamentului a determinat restaurarea fizicãºi hematologicã a animalelor de experienþã cu stare anemicã;principiile active conþinute în produs au proprietateade a activa funcþiile biologice ale animalelorBibliografie1.Wursschmidt F. - "Diagnosis and therapy of radiation induced normaltissue toxicity: Lung", Nuclear Medical Defense Conference, Abstracts,p.7-8, Federal Armed Forces Medical Academy, Germany, 20002. Zimmermann F. - "Diagnosis and therapy of radiationinduced tissue injuries: Liver", Nuclear Medical Defense Conference,Abstracts, p.9-10, Federal Armed Forces Medical Academy, Germany,2000.3.Zimmermann F., Geinitz H., Molls M. -"Diagnosis and therapy of radiationinduced tissue injuries: Gastrointestinal system", Nuclear MedicalDefense Conference, Abstracts, p.11-12, Federal Armed Forces MedicalAcademy, Germany, 2000.4.Geinitz H., Zimmermann F., Molls M. - "Diagnosis and therapy of radiationinduced tissue injuries: Kidneys", Nuclear Medical DefenseConference, Abstracts, p.13-14, Federal Armed Forces MedicalAcademy, Germany, 2000.5.Grosu A.L., Feldmann H.J., Molls M. -"Diagnosis and therapy of radiationinduced tissue injuries: Central Nervous System", Nuclear MedicalDefense Conference, Abstracts, p. 15-16, Federal Armed Forces MedicalAcademy, Germany, 2000.6.Meineke V. - "Diagnosis and therapy of radio-gene induced skinlesins", Nuclear Medical Defense Conference, Abstracts, p.17-18,Germany, 2000.7.Henge-Napoli M.H., Archimbaud M., Ansoborlo E., Gourmeon P. -Efficacy of 3,4,3-LIHOPO for reducing the retention of uranium in ratafter acute administration. Institute de Protection et de SureteNucleaire, IPSN, Fontenay aux Roses, France. International Journal ofRadiation Biology, 68(4): 389-393, Oct 19958.Durbin P.W., Kullgren B., Xu J., Raymond K.N. - New agents [Me-3,2-HOPO] for in vivo chelation of uranium (VI): efficacy and toxicity inmice of multidentate catecholate and hydroxypyridinonate ligands.Chemical Sciences Division, Ernest Orlando Lawrence BerkeleyNational Laboratory, CA 94720, USA. Health Physics, 72(6): 865-879,Jun 1997.9.Ramounet-Le Gall B., Grillon G., Rateau G., Burgada R., Bailly T.,Fritsch P. - Comparative decorporation efficacy of 3,4,3-LIHOPO, 4,4,4-LIHOPO and DTPA after contamination of rats with soluble forms of238Pu and 233U. Radiation Protection Dosimetry, 105(1-4): 535-538,200310.Henge-Napoli M.H., Ansoborlo E., Chazel V., Houpert P., GourmelonP. - Efficacy of Ethane-1-Hydroxy-1,1-Bis-phosphonate (EHBP) for thedecorporation of uranium after intramuscularly contamination in rats.International Journal of Radiation Biology. 75(11): 1473-1477, Nov199911.Oomen A.G., Tolls J., Sips A.J., Groten J.P. - In vitro intestinal lead[203Pb] uptake and transport in relation to speciation. UtrechtUniversity, The Netherlands. Archives of Environmental Contamination& Toxicology. 44(1): 116-124, Jan 2003.12.Stan C. - STANOSIMAGNE FF 6-006 - capsules, drug for internaluse, indicated for the radiobiological decontamination of Uranium,radio-nuclides and heavy metals, The 32-nd International ScientificSymposium of the Defence Research Agency, Chemistry and MedicalNBC Protection, Vol.II, p.32-39, Bucharest, Apr 2001.tratate, cu efecte somative imediate.Datele histologice ºi histochimice au evidenþiatefectul de restaurare biologicã activã prin tratamentul cuSTANOSIMAGNE prin care se iniþiazã ºi se susþin proceselebiologice de reconstituire a componentelor celularelezionate prin iradiere sau contaminare chimicã.Produsul farmaceutic administrat preclinic ºi clinicare efecte notabile atât asupra decontaminãrii radiobiologicein vivo cât ºi asupra restaurãrii ºi vindecãrii tegumentelorlezate prin arsurile produse de iradiere ºi substanþechimice. În urma tratamentului aplicat, dateleobþinute au arãtat cã tegumentele lezate se refac princreºterea numãrului de capilare ºi fibre elastice în dermullezional ºi perilezional, favorizându-se o vindecare identicãºi rapidã.13.Stan C. - Active biologic composition for NBC Medical Protection,STANOSIMAGNE FF 6-006 - capsules, The 17-th InternationalSymposium on Naval and Marine Education NAV-MAR-EDU,Romanian Naval Academy Constantza, Vol.III, p.323-331, May, 2001.14.Stan C., Cristea A.N., Istudor V., Mihele D., St?nescu V., Mitrea N.,Iovu M., Sahagia M., Dumitrescu G. - STANOSIMAGNE FF 6-006Capsules, medicine for radiobiological decontamination of Uranium,radionuclides and heavy metals, The XII-th National Congress ofPharmacy with International Participation, Publisher GENICOD Ltd.,Bucharest, Vol.II, 378-380, Oct 2002.15.Stan C., Cristea A.N., Sahagia M., Dumitrescu G.- STANOSIMAGNEFF 6-006 Ointment, medicine for external therapy of chemical or thermalburns and radiogen induced skin lesions, The XII-th NationalCongress of Pharmacy, with International Participation, PublisherGENICOD Ltd., Bucharest, Vol.II, 421-424, Oct 2002.16.Stan C. - Pharmaceutical product with recovery effect in NBC MeicalProtection, STANOSIMAGNE FF 6-006 - Ointment, The 17-thInternational Symposium on Naval and Marine Education NAV-MAR-EDU, Romanian Naval Academy Constantza, Vol.III, p.332-341, May2001.17.Stan C. - STANOSIMAGNE FF 6-006 - ointment, drug for externaluse, indicated for the radiobiological decontamination of Uranium,radio-nuclides and heavy metals, The 32-nd International ScientificSymposium of the Defence Research Agency, Chemistry and MedicalNBC Protection, Vol.II, p.83-90, Bucharest, Apr 2001.18.Finch C.S. - Radiation injury, Pathogenesis of radiation injury,Clinical effects of radiation exposure. HARRISON'S Principles ofInternal Medicine. Thirteenth Ed., 2482-2487, London 199419.Washington V.C.Jr., Sober J.A.- Skin cancer, Melanoma and otherpigmented skin lesions. HARRISON'S Principles of Internal Medicine.Thirteenth International Ed., 1866-1870, London 199420.Yves M. - Larousse - Dictionar de medicina, Ed. UniversulEnciclopedic, Bucuresti, 377, 433, 542-543, 565, 1998.21.Kocher D.C. - Relationship between kidney burden and radiationdose from chronic ingestion of U: implications for radiation standardsfor the public. Health and Safety Research Division, Oak Ridge NationalLaboratory, Health Physics. 57(1): 9-15, Jul. 198922.Kol R., Pelled O., Canfi A., Gilad Y., German U., Laichter Y.,Lantsberg S., Fuksbrauner R., Gold B. - The interference of medicalradionuclides with occupational in vivo gamma spectrometry. NuclearResearch Center Negev, Beer-Sheva, Israel. Health Physics. 84(6): 756-763, Jun.200323.Lenskaia R.V., Pivovarova A.I., Lukianova A.G., Bykova I.A.,Zakharova G.A., Zelenina E.V., Trubina N.M., Buiankin V.M., ChernovV.M., Petrukhin A.A. - [Results of screening hematological and cytochemicalblood studies of 906 children living in Bryansk Province atplaces with different intensities of soil contamination with cesium-137and strontium-90]. [Russian] Gematologiia i Transfuziologiia. 40(6): 30-34, Nov-Dec 1995.24.IFA-CNCAN, Bucureºti - Standarde de bazã de radioprotecþie. Edit.Institutul de Fizicã Atomicã Comisia Naþionalã pentru ControlulActivitãþilor Nucleare, 1-13, 20-47, Bucureºti 1998.106